Good article on drugs in testing and when they will be available

[charly8]

Comparison of 7-day monotherapy of Sovaldi vs. MK-3682 and ACH 3422 indicate a rate of viral clearance of Sovaldi > MK-3682 > ACH 3422.

Gilead will be reporting Phase 3 data on GS-5816 with Sovaldi in 3Q15 and could have this pan-genotypic combo on the market by the end of 2016.

Merck initiated a Phase 2 study with their triple combo in GT3 patients and could field a best-in-class pan-genotypic regimen in 2018, some two years behind Gilead's next generation.

Achillion’s nuke ACH 3422 suffers from poor bioavailability, has a tenuous IP position, and a slow pace of development.

JNJ’s nucleotide AL-335 acquired from Alios is in Phase 1 and, with access now to ACH 3102, JNJ could have a pan-genotypic therapy approved in the 2019 to 2020 time frame.

http://seekingalpha.com/article/3203006-gilead-merck-and-achillion-j-and-j-square-off-in-an-hcv-nuclear-showdown

[dragonslayer]

I wonder if the Gilead combo will  get Breakthrough status from the FDA for even earlier approval.